Company intelligence / Profile preview

JY BioMed

Ownership: Private
Development stage: Other

Overview

JY BioMed is a clinical-stage biotechnology company specializing in the development and manufacturing of recombinant humanized collagen (rhCollagen) using advanced synthetic biology. The company leverages a proprietary high-efficiency yeast expression platform to produce collagen that is structurally identical to human collagen, ensuring high biocompatibility and low immunogenicity. Their product portfolio targets medical aesthetics, wound care, and regenerative medicine, with several products already in the commercial or late-clinical stages in China. JY BioMed aims to replace animal-derived collagen with sustainable, high-purity recombinant alternatives for diverse healthcare applications.

Therapeutic areas: Women's HealthDermatology
Modalities: Recombinant proteinBiologic
Industry: Biotech

Drug pipeline

2 assets

anti-CEACAM6 HCAb-ADC

Preclinical

1 more asset in the full pipeline.

Beyond the preview

Go deeper on JY BioMed.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on JY BioMed.